Perinatal Exposure to Antiretroviral Agents: Risks and Benefits

References

1. ↵
   Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type-1 with zidovudine treatment. N Eng J Med 1994;331:1173–1180

   CrossRefPubMedWeb of Science
2. ↵
   US Centers for Disease Control. Public Health Service recommendations on use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1994;43:1–20
3. ↵
   Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States, June 23, 2004 [http://AIDSinfo.nih.gov]
4. ↵
   Stiehm ER, Lambert J, Mofenson L, et al. Efficacy of zidovudine and HIV hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group Protocol 185. J Infect Dis 1999;179:567–575

   Abstract/FREE Full Text
5. ↵
   Garcia PM, Kalish LA, Pitt J, et al. Maternal plasma HIV-1 RNA levels and risk of perinatal transmission. N Engl J Med 1999;341:394–402

   CrossRefPubMedWeb of Science
6. ↵
   Lindegren ML, Byers RH, Thomas P, et al. Trends in perinatal transmission of HIV/AIDS in the United States. JAMA 1999;282:531–538

   CrossRefPubMedWeb of Science
7. ↵
   Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomized controlled trial. Lancet 1999;353:773–780

   CrossRefPubMedWeb of Science
8. Guay L, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomized trial. Lancet 1999;354:795–802

   CrossRefPubMedWeb of Science
9. ↵
   Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra Study): a randomized, double blind, placebo controlled trial. Lancet 2002;359:1178–1186

   CrossRefPubMedWeb of Science
10. ↵
    Culnane M, Fowler M, Lee SS, et al. Lack of long term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women: Pediatric AIDS Trials Group Protocol 219/076 Teams. JAMA 1999;281:151–157

    CrossRefPubMedWeb of Science
11. Hanson IC, Antonelli TA, Sperling RS, et al. Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20:463–467

    PubMed
12. Caselli D, Klersy C, de Martino M, et al. Human immunodeficiency virus-related cancer in children: incidence and treatment outcome: report of the Italian Register. J Clin Oncol 2000;18:3854–3861

    Abstract/FREE Full Text
13. ↵
    Tuomala RE, Shapiro DE, Sorenson LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 2002;346:1863–1870

    CrossRefPubMedWeb of Science
14. ↵
    Blanche S, Tradieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999;354:1084–1089

    CrossRefPubMedWeb of Science
15. ↵
    Munnich A, Rotig A, Chretien, D., et al. Clinical presentation of mitochondrial disorders in childhood. J Inherit Metab Dis 1996;19:521–527

    CrossRefPubMedWeb of Science
16. ↵
    Barret B, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction in HIV exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS 2003;17:1769–1785

    CrossRefPubMedWeb of Science
17. ↵
    Perinatal Safety Review Working Group. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. J Acquir Immune Defic Syndr 2000;25:261–268
18. ↵
    Lipshultz SE, Easley KA, Orav EJ, et al. Absence of cardiac toxicity of zidovudine in infants: Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection Study Group. N Engl J Med 2000;343:759–766

    CrossRefPubMedWeb of Science
19. ↵
    Brinkman K, Ter Hofstede HJ, Burger DM, et al. Adverse effects on reverse transcriptase inhibitors: mitochondrial toxicity as a common path way. AIDS 1998;12:1735–1744

    CrossRefPubMedWeb of Science
20. ↵
    Gerschenson M, Erhart SW, Paik CY, et al. Fetal mitochondrial heart and skeletal muscle damage in erythrocebus patas monkeys exposed in utero to 3′-azido-3′-deoxythymidine. AIDS Res Human Retroviruses 2000;16:635–644

    CrossRefPubMedWeb of Science
21. ↵
    Gerschenson M, Nguyen V, Ewings EL, et al. Mitochondrial toxicity in fetal erythrocebus patas monkeys exposed transplacentally to zidovudine + lamivudine. AIDS Res Human Retroviruses 2004;20:91–100

    CrossRefPubMedWeb of Science
22. ↵
    Poirier MC, Dive RL, Al-Harti L, et al. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. J Acquir Immune Defic Syndr 2003;33:175–183
23. ↵
    Alimenti A, Burge D, Ogilvie A, et al. Lactic academia in HIV infants exposed to perinatal antiretroviral therapy. Pediatr Infect Dis J 2003;22:782–789

    PubMedWeb of Science
24. ↵
    The European Mode of Delivery Collaboration. Elective caesarian section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomized clinical trial. Lancet 1999;353:1035–1039

    CrossRefPubMedWeb of Science
25. ↵
    Anonymous. ACOG Committee opinion: scheduled cesarean delivery and the prevention of vertical transmission of HIV infection. Number 234, May 2000. Int J Gynaecol Obstet 2001;73:279–281

    CrossRefPubMed
26. ↵
    Ioannidid JP, Abrams EJ, Ammann A, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/mL. J Infect Dis 2001;183:539–545

    Abstract/FREE Full Text
27. ↵
    Beasley RP, Hwang LY, Lee, GC-Y, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and Hepatitis B vaccine Lancet 1983;2:1099–1102

    PubMedWeb of Science
28. ↵
    Centers for Disease Control. Protection against viral hepatitis. MMWR Morb Mortal Wkly Rep 1990;39:1–26

    PubMed
29. Mofenson L. Perinatal exposure to zidovudine: benefits and risks N Engl J Med 2000;343:803–805

    CrossRefPubMedWeb of Science